GlassScriptPhysician profile
Daniel M Hafez
NPI 1134534621
$272,597.74
in general payments reported to CMS, 2019-2025
24 companies · $162K in 2025
The $162K reported for 2025 was more than what 98% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $174 · 2021: $61K · 2022: $6,479 · 2023: $13K · 2024: $31K · 2025: $162K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $102K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Travel and Lodging: $37K · Food and Beverage: $8,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $102,374.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,450.00 |
| Travel and Lodging | $37,219.11 |
| Food and Beverage | $8,988.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $81,998.37 | 2021-2025 | Excelsius Gps, Mars, Elsa |
| Arthrex, INC. | $62,591.21 | 2025 | |
| Nuvasive, INC. | $60,535.56 | 2021-2022 | |
| Elliquence, LLC | $33,233.26 | 2024-2025 | Trigger-Flex |
| Depuy Synthes Products, INC. | $13,068.53 | 2024-2025 | Velys |
| Spineology INC. | $9,082.86 | 2023-2024 | Optimesh Expandable Interbody Fusion System |
| Alphatec Spine, INC | $4,006.86 | 2022-2025 | Other - Miscellaneous, Biologics |
| Medtronic, INC. | $3,691.23 | 2023-2025 | Cd Horizon Spinal System, Midas Rex, Mazor X System |
| Depuy Synthes Sales INC. | $729.53 | 2022-2025 | Teligen, Spine & Trauma 3d Navigation, Arch |
| Stryker Corporation | $623.17 | 2020-2022 | |
| Expanding Innovations, INC. | $599.30 | 2025 | X-Pac |
| Integra Lifesciences Corporation | $492.74 | 2019-2025 | Cusa Clarity, Codman Certas, Codman Hakim |
| Corelink, LLC | $289.63 | 2022 | |
| Medical Device Business Services, INC. | $279.43 | 2023-2024 | Expedium, Conduit |
| Nexus Spine, LLC | $278.29 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elite Orthopedics, LLC | $201.58 | 2024-2025 | |
| Abbott Laboratories | $175.01 | 2022 | |
| Centinel Spine, LLC | $169.99 | 2025 | Prodisc C Vivo, Prodisc L |
| Si-Bone, INC. | $146.48 | 2022 | |
| Retropsoas Technologies, LLC | $137.98 | 2025 | |
| Kls-Martin L.P. | $125.00 | 2022 | |
| Trackx Technology, INC. | $66.29 | 2024 | |
| Augmedics INC. | $53.11 | 2023-2025 | Xvision |
| Zimvie INC. | $22.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,198.60 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hafez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.